Royalty Pharma plc Insider Trading

RPRX

Last 12 months

Insiders sold $92.8M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jun 2023.

Net open-market

−$92.8M

0 buys · 38 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Jun 2023

Jun 28, 2023

Get an email when RPRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 5	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	4,126	$57.10	236K	18%	Form 4
Sep 28	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	4,126	$57.88	239K	15%	Form 4
Sep 22	Christopher Hite EVP & Chairman, Partnering	Sold10b5-1 plan 2 parts	100,000	$58.53 average	$5.85M	25%	Form 4
Aug 18	Christopher Hite EVP & Chairman, Partnering	Sold10b5-1 plan	100,000	$59.97	$6M	20%	Form 4
Aug 13	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	11,002	$58.68 average	646K	18%	Form 4
Jul 1	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	9,099	$55.88	508K	32%	Form 4
Jun 30	Christopher Hite EVP & Chairman, Partnering	Sold10b5-1 plan 4 parts	130,000	$56.50 average	$7.35M	21%	Form 4
Jun 24	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	9,098	$55.18	502K	50%	Form 4
Jun 23	Christopher Hite EVP & Chairman, Partnering	Sold10b5-1 plan 2 parts	150,000	$54.39 average	$8.16M	19%	Form 4
May 26	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan	64,399	$53.98	$3.48M	56%	Form 4
May 20	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	13,684	$52.75	722K	27%	Form 4
May 14	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	13,684	$53.06	726K	21%	Form 4
May 14	Gregory Norden Director	Sold10b5-1 plan	3,045	$53.00	161K	1.6%	Form 4
Apr 28	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	34,791	$49.78 average	$1.73M	28%	Form 4
Apr 1	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	34,791	$48.33 average	$1.68M	22%	Form 4
Mar 23	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	34,791	$45.53 average	$1.58M	18%	Form 4
Mar 2	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 4 parts	34,791	$46.78 average	$1.63M	15%	Form 4
Feb 23	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	34,791	$45.32 average	$1.58M	13%	Form 4
Feb 2 – 4	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 6 parts	243,541	$42.54 average	$10.4M	51%	Form 4
Jan 30	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	20,000	$41.09	822K	43%	Form 4
Jan 23	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	20,000	$40.26	805K	30%	Form 4
Jan 20	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	69,582	$39.35 average	$2.74M	13%	Form 4
Jan 16	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	20,000	$39.52	790K	23%	Form 4
Jan 9	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	20,000	$40.78	816K	19%	Form 4
Jan 2	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	20,000	$38.48	770K	16%	Form 4
Jan 2	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	69,582	$38.42 average	$2.67M	11%	Form 4
Dec 26, 2025	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	20,000	$39.32	786K	14%	Form 4
Dec 19, 2025	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	20,000	$38.38	768K	12%	Form 4
Dec 17, 2025 – Dec 18, 2025	George W. Lloyd EVP, Investments & CLO	Sold10b5-1 plan 2 parts	110,000	$38.55 average	$4.24M	12%	Form 4
Dec 16, 2025	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan	20,000	$38.32	766K	11%	Form 4
Dec 15, 2025	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	69,582	$38.36 average	$2.67M	10%	Form 4
Dec 5, 2025	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan 2 parts	41,576	$39.15 average	$1.63M	18%	Form 4
Dec 3, 2025	George W. Lloyd EVP, Investments & CLO	Sold10b5-1 plan	110,000	$39.77	$4.37M	11%	Form 4
Dec 1, 2025	Marshall Urist EVP, Research & Investments	Sold10b5-1 plan 2 parts	41,575	$39.92 average	$1.66M	15%	Form 4
Dec 1, 2025	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	69,582	$39.87 average	$2.77M	9.2%	Form 4
Nov 24, 2025	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 4 parts	69,582	$38.55 average	$2.68M	8.4%	Form 4
Nov 19, 2025	George W. Lloyd EVP, Investments & CLO	Sold10b5-1 plan 8 parts	135,426	$38.34 average	$5.19M	12%	Form 4
Nov 17, 2025	Terrance P. Coyne EVP & CFO	Sold10b5-1 plan 2 parts	69,594	$39.30 average	$2.74M	7.7%	Form 4
Aug 11, 2025	Gregory Norden Director	SoldNo plan	33,500	$36.23	$1.21M	15%	Form 4

Oct 510b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 4,126 at $57.10
236K
18% of stake
Sep 2810b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 4,126 at $57.88
239K
15% of stake
Sep 2210b5-1 plan
Christopher Hite
EVP & Chairman, Partnering · sold 100,000 at avg $58.53
$5.85M
25% of stake
Aug 1810b5-1 plan
Christopher Hite
EVP & Chairman, Partnering · sold 100,000 at $59.97
$6M
20% of stake
Aug 1310b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 11,002 at avg $58.68
646K
18% of stake
Jul 110b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 9,099 at $55.88
508K
32% of stake
Jun 3010b5-1 plan
Christopher Hite
EVP & Chairman, Partnering · sold 130,000 at avg $56.50
$7.35M
21% of stake
Jun 2410b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 9,098 at $55.18
502K
50% of stake
Jun 2310b5-1 plan
Christopher Hite
EVP & Chairman, Partnering · sold 150,000 at avg $54.39
$8.16M
19% of stake
May 2610b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 64,399 at $53.98
$3.48M
56% of stake
May 2010b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 13,684 at $52.75
722K
27% of stake
May 1410b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 13,684 at $53.06
726K
21% of stake
May 1410b5-1 plan
Gregory Norden
Director · sold 3,045 at $53.00
161K
1.6% of stake
Apr 2810b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 34,791 at avg $49.78
$1.73M
28% of stake
Apr 110b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 34,791 at avg $48.33
$1.68M
22% of stake
Mar 2310b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 34,791 at avg $45.53
$1.58M
18% of stake
Mar 210b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 34,791 at avg $46.78
$1.63M
15% of stake
Feb 2310b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 34,791 at avg $45.32
$1.58M
13% of stake
Feb 2 – 410b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 243,541 at avg $42.54
$10.4M
51% of stake
Jan 3010b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 20,000 at $41.09
822K
43% of stake
Jan 2310b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 20,000 at $40.26
805K
30% of stake
Jan 2010b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 69,582 at avg $39.35
$2.74M
13% of stake
Jan 1610b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 20,000 at $39.52
790K
23% of stake
Jan 910b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 20,000 at $40.78
816K
19% of stake
Jan 210b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 20,000 at $38.48
770K
16% of stake
Jan 210b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 69,582 at avg $38.42
$2.67M
11% of stake
Dec 26, 202510b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 20,000 at $39.32
786K
14% of stake
Dec 19, 202510b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 20,000 at $38.38
768K
12% of stake
Dec 17, 2025 – Dec 18, 202510b5-1 plan
George W. Lloyd
EVP, Investments & CLO · sold 110,000 at avg $38.55
$4.24M
12% of stake
Dec 16, 202510b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 20,000 at $38.32
766K
11% of stake
Dec 15, 202510b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 69,582 at avg $38.36
$2.67M
10% of stake
Dec 5, 202510b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 41,576 at avg $39.15
$1.63M
18% of stake
Dec 3, 202510b5-1 plan
George W. Lloyd
EVP, Investments & CLO · sold 110,000 at $39.77
$4.37M
11% of stake
Dec 1, 202510b5-1 plan
Marshall Urist
EVP, Research & Investments · sold 41,575 at avg $39.92
$1.66M
15% of stake
Dec 1, 202510b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 69,582 at avg $39.87
$2.77M
9.2% of stake
Nov 24, 202510b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 69,582 at avg $38.55
$2.68M
8.4% of stake
Nov 19, 202510b5-1 plan
George W. Lloyd
EVP, Investments & CLO · sold 135,426 at avg $38.34
$5.19M
12% of stake
Nov 17, 202510b5-1 plan
Terrance P. Coyne
EVP & CFO · sold 69,594 at avg $39.30
$2.74M
7.7% of stake
Aug 11, 2025No plan
Gregory Norden
Director · sold 33,500 at $36.23
$1.21M
15% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RPRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with RPRX

CompareIntrinsic value

SRPTSarepta Therapeutics Inc.

$18.99+2.43%51

AMRXAmneal Pharmaceuticals Inc.

$19.95-1.29%57

UTHRUnited Therapeutics Corporation

$608.49+1.19%78

ALKSAlkermes plc

$45.90+0.46%36

BMRNBiomarin Pharmaceutical Inc.

$57.13+2.64%47

PAHCPhibro Animal Health Corporation

$39.43+4.73%57

ALNYAlnylam Pharmaceuticals Inc

$161.08+0.74%81

INDVIndivior Pharmaceuticals, Inc.

$36.28+2.57%80

Held by ETFs

RPRX is in 169 US ETFs. The largest of them, with RPRX's weight in each:

Spot a number that looks wrong? Check it in RPRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RPRX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.